Adamis Pharmaceuticals stock appears to show signs of accumulation by large players into a consolidation pattern called a Symmetrical Triangle. Shares of Adamis Pharmaceuticals Corporation ADMP soared more than 50% back on June 15th and 16th after the FDA approved the company’s Epinephrine injection. This will be a lost cost alternative to the EpiPen. I first purchased this back on June 15th, got stopped out for a loss, and now I’m taking another run at it with a purchase of ADMP on June 30, 2017.
Adamis Pharmaceuticals Stock Chart
Rising large players volume shows accumulation into the apex of the Symmetrical Triangle pattern.
The stock of PRA Health Sciences looks like a compelling entry on a momentum squeeze after the company announced a partnership with Jumo.
PRA Health recently announced a partnership with Jumo, a global provider of educational health care information. The company says that PRA Health can leverage on Jumo’s solid education-information system to bridge the gap between caregivers and patients while conducting pediatric clinical trials.
PRA Health Sciences Stock Chart
Large players have been selling the stock so I think you have to be cautious before taking a swing long entry. We have had several Pocket Pivot signals (blue dots) which is a bullish sign.
There is reduced volatility while prices have been consolidating setting up a momentum squeeze.
There is a very little resistance above the current price.
GDP for Q1 was revised upward to 1.4% on an increase in consumer spending. The US economy enters its ninth year of economic growth in July.
The first GDP estimate for Q1 was originally reported at 0.7%. So Q1 GDP grew at twice the rate as originally thought. That’s great. Obviously 1.4% growth is not great but to have GDP growth at twice the rate than originally thought is awesome.
The idea that the Federal Reserve has hiked rates too far, too fast, and thus was crashing GDP is pushed a little ways off with this Q1 GDP upward revision. Clearly economic growth is not slowing as rapidly as everyone originally thought.
Some economists suspect the Q1 GDP number still underestimates the true rate of increase in the US. Regardless of the upward revision to GDP, President Trump’s stated goal of quickly boosting annual GDP to 3% remains a struggle.
Analysts estimate that the U.S. market will grow at a 3% rate in the April-to-June interval, although the downturn in equipment orders and shipments reported earlier this week increases the danger that industry investment will supply less of a boost than expected.
A sustained average economic growth rate of 3% hasn’t been achieved in the US since the 1990s. The U.S. economy has grown an average of 2% since 2000.
Initial indications that GDP has accelerated in the next quarter are unlikely in the face of recent data on retail sales and manufacturing production.
The Bear ETF 3X FAZ has set up into a nice scalp trade IMO. What’s crazy too is the positive divergence between the price and the Effective Volume which tracks large players.
Bear ETF 3x
The positive divergence on large players looks awesome.
This trade will be very short in duration as the plan is to go for a quick scalp trade unless it turns into something more amazing. Get in, hit it, and get out quick is the name of the game in this trade.
I bought FAZ this morning for a quick scalp trade in my personal trading account.
The stock chart of Cerner Corporation shows a momentum squeeze candidate on excellent sales growth and new business from the Carolinas HealthCare System (CHS).
Cerner announced on June 21, 2017, that the Carolinas HealthCare System (CHS) has selected Cerner’s HealtheIntent public health management platform to organize and manage care for its more than 12 million individual interactions every year across its facilities and clinically integrated network, Carolinas Physician Alliance (CPA).
HealtheIntent is intended to aggregate data in real-time from several sources to produce a single, comprehensive view of someone’s experiences throughout the continuum of health and care.
The objective is to equip medical professionals with a holistic and timely picture of a patient’s connections through CHS, in addition to provide system wide insights to ultimately improve quality of care and reduce costs for the entire CHS patient population.
Cerner Corporation Stock Chart
CERN presents a good setup pattern. Prices have been consolidating lately and a momentum squeeze has formed on the chart.
There is a resistance zone just above the current price starting at 68.32. Right above this resistance zone may be a good entry point in Cerner Corporation. There is a support zone below the current price at 67.04, a stop order could be placed below this zone.
Gigamon stock looks like a compelling swing long entry on a momentum squeeze. Fundamentally, the company has averaged annual sales for the past 5 years of 35.5%.
Gigamon Stock Chart
GIMO present a good swing long setup opportunity. There is reduced volatility while prices have been consolidating, signaling a momentum squeeze.
There is a resistance zone just above the current price starting at 40.28. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 40.09, a stop order could be placed below this zone. Large players are showing interest in GIMO over the last couple of days, which is a good sign. Another positive sign is the recent Pocket Pivot signal.
On Wednesday, the Fed said banks such as JPMorgan Chase & Co and Bank of America Corp, had passed the second, more demanding part of its yearly stress test. The results demonstrated that many haven’t only built up adequate capital buffers, but improved risk management processes too. Charts of the best bank stocks to buy now are below.
It was the first time in years of annual “stress tests” that each bank assessed by the Fed won approval for its capital strategies.
Fed Governor Jerome Powell, who’s acting as regulatory guide for the U.S. central bank, said the process has inspired all the largest banks to attain good capital levels.
The Fed on Wednesday announced the results of the second round of its yearly stress tests. Those permitted to increase dividends or repurchase shares contain the four largest U.S. banks — JPMorgan Chase, Bank of America, Citigroup and Wells Fargo. These large banks are the best bank stocks to buy now.
Following the results today, numerous banks quickly jumped in with announcements of dividend boosts and share buyback plans.
The second part of this seventh annual check-up tested the banks to decide if their existing plans for paying out capital to shareholders would still let them keep lending if hit by another financial crisis and serious recession.
Banks have a total of approximately $1.2 trillion in capital reserves as of the fourth quarter of this past year, an increase of $750 billion over 2009. They’re expected to pay out to shareholders 100 percent of the net revenue during the next four quarters, compared with 65 percent in the same period last year.
Best Bank Stocks To Buy Now
Bullish Pocket Pivot pattern on June 28, 2017. Feels a little like chasing at this level. I would prefer to wait for a consolidation move before taking a swing long entry.
Powerful breakout move but chasing breakouts is a losers strategy. I would prefer to wait for a pullback at least a consolidation period before taking a long entry.
I like the sideways consolidation pattern in Bank of America. We also had a bullish Pocket Pivot signal on June 28, 2017.
Wells Fargo has major resistance at $55. An entry above this level is prudent. The Twiggs Money Flow is just starting to round up so it has less of a chasing feel to it.
I will keep hunting for the best bank stocks to buy now.
A CNN producer is caught on hidden camera admitting that so called “news” about Russia ties to the Trump Administration are fake news and are really all about ratings.
I said months ago on a Saturday show that the whole Russia thing was fake news. Either a real stupid YouTuber or a democrat operative posted below the show that I was way off about Russia and that I should stick with talking about the stock market.
So Bloomberg, CNBC, the Wall Street Journal, they can talk politics and publish fake news stories about Trump and Russia but little old nobody me, I’m the one that can’t talk about Russia? Talk about straining out a gnat yet swallowing a camel. It was a lame post and read more like a manipulative psy-ops and so I banned the YouTuber from commenting on my videos.
Here is the hidden video of a CNN producer talking about why the network keeps running Russia stories: